Correction: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study by Djabarouti, Sarah et al.
After publication of our recent article [1], we noticed an 
error in the unit for the area under the time-
concentration curve between 0 and 12 hours (AUC0-12h). 
Th  roughout the article and table 1 the unit should be 
mg·h/L (mg multiplied by hour per L) not mg/hour/L .
Th   e correct table is given here as Table 1.
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© 2011 BioMed Central LtdTable 1. Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical 
outcome (univariate analysis)
   Total  Successes  Failures
Inclusion characteristic  n = 26  n = 17  n = 8  P valuea
Demographic     
 Females/Males,  number  16/10  12/5  4/4  0.28b
  Age, years  46 (35-61)a  46.5 (35-61)  46 (38-61)  0.9
  Body weight, kg  60 (56-75)  60 (56-75)  62 (58-82.5)  0.62
Disease     
  Duration before entry, months  11 (7-14)  11 (7-12)  10 (6-13)  0.30
  SLEDAI score  0 (0-2)  0 (0-2)  0 (0-2)  0.20
  C3, g/L  1 (0.6-1.1)  1 (0.9-1.1)  0.8 (0.56-0.96)  0.21
  C4, g/L  0.2 (0.1-0.2)  0.2 (0.1-0.2)  0.2 (0.16-0.24)  0.78
  Anti-double-stranded DNA, IU/mL  24 (6-51)  8 (1 -32)  38 (9 -55)  0.19
Biological     
  GFR, mL/minute  95 (67-125)  95 (67-125)  93.5 (76-109)  0.64
  Albumin, g/L  40 (39.8-43.8)  40 (37.9-43.8)  42.8 (40-46.9)  0.33
  Aspartate aminotransferase, IU/L  23 (19-26)  23 (17.5-24.5)  28 (20-33)  0.26
  Alanine aminotransferase, IU/L  22 (15-29)  19 (13-24.5)  25 (19-37)  0.21
  γ-Glutamyltransferase, IU/L  24 (17-63)  23 (17-21)  42 (17-61)  0.92
Treatment     
  MMF, g/day  2 (2-2)  2 (2-2)  2 (2-2)  0.9
  Corticosteroids, mg/day  11 (7-35)  10 (5-20)  15 (7-45)  0.37
  Months of MMF therapy  2 (1-3)  2 (1-3)  2 (1-3)  0.56
  Months of corticosteroids  10 (6-13)  10 (5-15)  9 (5-14)  0.12
MPA pharmacokinetic parameters       
 AUC0-12 h, mg·hour/L  64.7 (38.2-82)  73.1 (61.8-95)  37.7 (32-43.7)  0.003
 C max, mg/L  16.1 (9.5-18.5)  16.3 (9.7-17.4)  13.3 (7-22.5)  0.69
 T max, hours  1 (1-2)  1 (1-2)  1.1 (1-2)  0.82
 C 12 h, mg/L  2.4 (1.5-4.1)  3.7 (2.3-4.9)  1.5 (0.6-2.1)  0.008
MPAG pharmacokinetic parameters       
 AUC0-12 h, mg·hour/L  775.3 (475-1,026)  791 (635-1,166)  678.8 (426-840.6)  0.22
 T max, hours  2 (2-3)  2.3 (2-3)  1.3 (1-2)  0.01
 C 12 h, mg/L  32.1 (24.3-41.9)  34.7 (26.4-49.2)  29.8 (15.5-40)  0.26
MPAG/MPA AUC0-12 h ratio  11.5 (8.3-20.7)  10.9 (6.2-14.8)  18.7 (14.1-22.7)  0.07
MPAG/MPA C12 h ratio  11.5 (6.8-17.3)  10.2 (6.3-15)  18.7 (11.5-47.2)  0.02
Values are expressed as median (interquartile range) unless stated otherwise. aMann-Whitney U test; bFisher exact test. AUC0-12 h, area under the plasma 
concentration-versus-time curves for hours 0 to 12; C12 h, 12-hour trough concentration; Cmax, maximal concentration; GFR, glomerular fi  ltration rate (estimated with 
the Cockcroft-Gault formula); MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; SLEDAI, Systemic Lupus Erythematosus 
Disease Activity Index; Tmax, time to maximal concentration.
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